Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Bristol-Myers Squibb is conducting a Phase 2/3 clinical study titled A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis With an Inadequate Response to Conventional Therapy. The study aims to assess the effectiveness and safety of oral Ozanimod in achieving and maintaining clinical remission in pediatric patients with moderate to severe ulcerative colitis who have not responded adequately to conventional treatments.
Intervention/Treatment: The study tests the drug Ozanimod, administered orally in varying doses. Ozanimod is designed to help achieve and maintain remission in patients with ulcerative colitis.
Study Design: This is an interventional study with a randomized allocation and a parallel intervention model. It employs quadruple masking, meaning that the participant, care provider, investigator, and outcomes assessor are all blinded. The primary purpose of the study is treatment.
Study Timeline: The study began on May 30, 2022, and the latest update was submitted on July 22, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
Market Implications: The ongoing study could significantly impact Bristol-Myers Squibb’s stock performance, especially if Ozanimod proves effective. Positive results may enhance investor sentiment and position the company favorably against competitors in the ulcerative colitis treatment market.
Closing Sentence: The study is currently recruiting, with further details available on the ClinicalTrials portal.